"Cannabidiol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compound isolated from Cannabis sativa extract.
| Descriptor ID |
D002185
|
| MeSH Number(s) |
D02.455.849.090.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cannabidiol".
Below are MeSH descriptors whose meaning is more specific than "Cannabidiol".
This graph shows the total number of publications written about "Cannabidiol" by people in this website by year, and whether "Cannabidiol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cannabidiol" by people in Profiles.
-
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program. Epilepsia Open. 2024 Oct; 9(5):1816-1825.
-
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program. Epilepsia. 2023 08; 64(8):e156-e163.
-
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023 01; 359:114238.
-
Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis. J Crohns Colitis. 2021 Jun 22; 15(6):1032-1048.
-
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021 03 01; 78(3):285-292.
-
Proposal to optimize evaluation and treatment of Febrile infection-related epilepsy syndrome (FIRES): A Report from FIRES workshop. Epilepsia Open. 2021 03; 6(1):62-72.
-
A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020 09 01; 161(9):2191-2202.
-
Response to Casarett et al. (doi: 10.1089/jpm.2018.0658): Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. J Palliat Med. 2019 11; 22(11):1301.
-
Open-label use of highly purified CBD (Epidiolex?) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018 09; 86:131-137.
-
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018 May 17; 378(20):1888-1897.